The clinical trial for alvocidib, sponsored by Sumitomo Pharma America, Inc., was aimed at evaluating its efficacy in patients with relapsed or refractory acute myeloid leukemia (AML) following treatment with venetoclax combination therapy. However, the study was terminated due to a business decision on November 17, 2020, with the last patient follow-up completed by May 14, 2021. This termination indicates potential challenges in the commercial viability of alvocidib, particularly in a competitive landscape where other therapies for AML, including venetoclax, are gaining traction. The decision to halt development may reflect insufficient efficacy or safety data to support further investment, necessitating a thorough review of the competitive landscape and market positioning for alternative therapies targeting AML.